Perth, Australia—A single injection of a gene therapy construct rAAV.sFLlt-1 for advanced age-related macular degeneration (AMD) has shown safety and efficacy through 3 years in a small cohort, said Ian J. Constable, MBBS.

The investigator-initiated study (supported by Avalanche Biotechnologies) has 3-year data from a phase I/IIa study on AVA-101 (also known as sFlt-1). Prof. Constable noted the idea was that this single injection might be able to continuously secrete a therapeutic protein over an extended period to avoid the need for frequent injections in the neovascular AMD patient.

“All patients were recruited with wet macula and had [undergone] anti-vascular endothelial growth factor therapy beforehand,” said Prof. Constable, professor of ophthalmology, Centre for Ophthalmology and Visual Science (incorporating Lions Eye Institute), The University of Western Australia, Perth. “When they were recruited, they all had ranibizumab at day 0 and day 28.”

Results published in 2015 on the first eight treated subjects “showed that at 1 year in the pilot study there was no loss of vision and there were minimal or no rescues required. Likewise, the center point thickness which was reduced with the booster doses at the beginning was largely maintained, although the retinal thickness was still above normal in some of the cases,” Prof. Constable said.

0 Comments

You must be signed in to leave a comment. Registering is fast and free!

All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.